RMD · NYSE
ResMed (RMD) Stock Price & Fundamentals
ResMed (RMD) closed at $885.44 on Oct 9, 2026, up 0.42% from the previous close of $881.74.
Share price, past year
1Y −1.56%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $885.44 |
| Sep 30, 2026 | $865.41 |
| Aug 31, 2026 | $916.91 |
| Jul 31, 2026 | $907.61 |
| Jun 30, 2026 | $887.09 |
| May 29, 2026 | $875.62 |
| Apr 30, 2026 | $886.38 |
| Mar 31, 2026 | $933.28 |
| Feb 27, 2026 | $962.31 |
| Jan 30, 2026 | $936.43 |
| Dec 31, 2025 | $912.33 |
| Nov 28, 2025 | $932.69 |
| Oct 31, 2025 | $942.87 |
Key statistics
- Market cap
- $127.72B
- P/E (TTM)
- 84.9
- EPS (TTM)
- $10.43
- Revenue (TTM)
- $5.65B
- Net income (TTM)
- $1.52B
- Shares outstanding
- 144.2M
- Dividend yield
- 0.27%
- 52-week range
- $862.34 – $970.24
ResMed's market cap is $127.72B, based on a share price of $885.44 and 144.2M shares outstanding as of Jun 30, 2026.
Financials
ResMed reported revenue of $5.65B for fiscal 2026, up 9.85% from fiscal 2025.
ResMed earned net income of $1.52B in fiscal 2026, a net margin of 26.9%.
Fiscal 2026 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended Jun 30, 2026 | $5.65B | +9.9% | $1.52B | 26.9% | $10.43 | $1.65B |
| FY2025ended Jun 30, 2025 | $5.15B | +9.8% | $1.40B | 27.2% | $9.51 | $1.66B |
| FY2024ended Jun 30, 2024 | $4.69B | +11.0% | $1.02B | 21.8% | $6.92 | $1.30B |
| FY2023ended Jun 30, 2023 | $4.22B | +18.0% | $897.56M | 21.3% | $6.09 | $573.63M |
| FY2022ended Jun 30, 2022 | $3.58B | +11.9% | $779.44M | 21.8% | $5.30 | $216.31M |
| FY2021ended Jun 30, 2021 | $3.20B | +8.1% | $474.51M | 14.8% | $3.24 | $634.01M |
| FY2020ended Jun 30, 2020 | $2.96B | +13.4% | $621.67M | 21.0% | $4.27 | $706.93M |
| FY2019ended Jun 30, 2019 | $2.61B | +11.4% | $404.59M | 15.5% | $2.80 | $390.34M |
| FY2018ended Jun 30, 2018 | $2.34B | +13.2% | $315.59M | 13.5% | $2.19 | $442.45M |
| FY2017ended Jun 30, 2017 | $2.07B | — | $342.28M | 16.6% | $2.40 | $351.83M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2026ended Jun 30, 2026 | $1.46B | $383.43M | $2.64 |
| Q3 FY2026ended Mar 31, 2026 | $1.43B | $398.73M | $2.74 |
| Q2 FY2026ended Dec 31, 2025 | $1.42B | $392.59M | $2.68 |
| Q1 FY2026ended Sep 30, 2025 | $1.34B | $348.54M | $2.37 |
| Q4 FY2025ended Jun 30, 2025 | $1.35B | $379.71M | $2.58 |
| Q3 FY2025ended Mar 31, 2025 | $1.29B | $365.04M | $2.48 |
| Q2 FY2025ended Dec 31, 2024 | $1.28B | $344.62M | $2.34 |
| Q1 FY2025ended Sep 30, 2024 | $1.22B | $311.36M | $2.11 |
Company profile
- Name
- ResMed Inc.
- Ticker
- RMD
- Exchange
- NYSE
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 9001 Spectrum Center Blvd., San Diego, CA 92123
- Incorporated in
- DE
- Fiscal year ends
- June
- SEC CIK
- 0000943819
Recent SEC filings
- Sep 1, 2026
- Aug 17, 2026
- Aug 13, 2026
- Aug 6, 2026
- Jul 7, 2026
- May 1, 2026
- Apr 30, 2026
- Apr 30, 2026
Frequently asked questions
What is ResMed's stock price?
ResMed (RMD) closed at $885.44 on Oct 9, 2026, up 0.42% from the previous close of $881.74.
What is ResMed's market cap?
ResMed's market cap is $127.72B, based on a share price of $885.44 and 144.2M shares outstanding as of Jun 30, 2026.
How much revenue does ResMed make?
ResMed reported revenue of $5.65B for fiscal 2026, up 9.85% from fiscal 2025.
What is RMD's P/E ratio?
ResMed's price-to-earnings ratio is 84.9, based on trailing twelve-month diluted EPS of $10.43.
Does ResMed pay a dividend?
Yes. ResMed declared $2.40 per share in dividends over the last four quarters, a yield of 0.27%.
Sources and methodology
Fundamentals come from ResMed Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures